Rationale and design of the granulocyte-macrophage colony stimulating factor in peripheral arterial disease (GPAD-3) study

Lower extremity peripheral arterial disease (PAD) is a public health problem and many patients with PAD experience claudication despite adequate medical and/or surgical management. Mobilization of endogenous progenitor cells using Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) is a novel therapeutic option that has shown promising results in experimental models and phase I/IIA trials. The GPAD-3 trial will study the effect of two successive administrations of GM-CSF at 3-month interval for improving claudication among patients with lower extremity PAD.

Source: Contemporary Clinical Trials - March 3, 2020 Category: Radiology Authors: Anurag Mehta, Kreton Mavromatis, Yi-An Ko, Steven C. Rogers, Devinder S. Dhindsa, Cydney Goodwin, Risha Patel, Mohammad A. Martini, Mahadev Prasad, Ali Mokhtari, Iraj G. Hesaroieh, Stephen C. Frohwein, Michael H. Kutner, Arash Harzand, Bryan J. Wells, Yaz Source Type: research